Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05077800 · ClinicalTrials.gov registry record · Phase 2
FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer
A Phase 2 study of Pancreatic Adenocarcinoma and Pancreatic Adenocarcinoma Metastatic, sponsored by Colin D. Weekes, M.D., PhD.
- Active
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 4
- Study locations
NCT05077800 is a Phase 2 study of Pancreatic Adenocarcinoma and Pancreatic Adenocarcinoma Metastatic that is active but no longer recruiting, run by Colin D. Weekes, M.D., PhD. The registered enrollment target is 70 participants, below the 99,464-participant average among 62 other Pancreatic Adenocarcinoma trials with a reported enrollment target (100% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT05077800, a Phase 2 study of Pancreatic Adenocarcinoma and Pancreatic Adenocarcinoma Metastatic, is active but no longer recruiting, sponsored by Colin D. Weekes, M.D., PhD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to find out if an experimental drug will prevent metastatic pancreatic adenocarcinoma from becoming resistant to standard treatment for the disease. The names of the study drugs involved in this study are: * 9-ING-41 * Losartan * Ferumoxytol * FOLFIRINOX (made up of 4 different drugs): * 5-Fluorouracil (5-FU) * Oxaliplatin * Irinotecan * Leucovorin
Conditions Studied
Interventions
- DRUG Losartan
- DRUG 9-ING-41
- DRUG FOLFIRNINOX
Study Locations (4)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Massachusetts General Hospital - Charlestown
Colorado
- University of Colorado Cancer Center - Aurora
Washington
- University of Washington School of Medicine - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2022-03-21 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05077800
The ClinicalTrials.gov registry entry for NCT05077800 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 99,464-participant average among 62 other Pancreatic Adenocarcinoma trials with a reported enrollment target (100% lower). The listed sponsor is Colin D. Weekes, M.D., PhD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 3 interventions - of which Losartan is the first listed.
NCT05077800 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, Colorado, Washington.
Frequently Asked Questions
What is clinical trial NCT05077800 about?
NCT05077800 is a clinical study titled "FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer". The purpose of this study is to find out if an experimental drug will prevent metastatic pancreatic adenocarcinoma from becoming resistant to standard treatment for the disease. The names of the study drugs involved in this study are: * 9-ING-41 * Losartan * Ferumoxytol * FOLFIRINOX (made up of 4 ...
What is the current status of trial NCT05077800?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2022-03-21. Estimated completion is 2026-07-31.
What conditions does trial NCT05077800 study?
This clinical trial studies the following conditions: Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic.
What interventions are being tested in trial NCT05077800?
The interventions under investigation include: Losartan (DRUG), 9-ING-41 (DRUG), FOLFIRNINOX (DRUG).
Who is sponsoring clinical trial NCT05077800?
This trial is sponsored by Colin D. Weekes, M.D., PhD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05077800 being conducted?
This trial has 4 study locations across Colorado, Massachusetts, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
RECRUITING · Phase 2
-
A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)
RECRUITING · Phase 2
-
Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
-
9-ING-41 in Patients with Advanced Cancers
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Pancreatic Adenocarcinoma
All registered trials for this condition
Pancreatic Adenocarcinoma Metastatic
All registered trials for this condition
Colorado
All trials with a study site in Colorado
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.